Inovio Pharmaceuticals/INO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

Ticker

INO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jacqueline Shea

Employees

122

Headquarters

San diego, United States

INO Metrics

BasicAdvanced
$262M
Market cap
-
P/E ratio
-$5.54
EPS
0.99
Beta
-
Dividend rate
$262M
0.98526
$14.75
$3.89
428K
4.773
-63.15%
-85.09%
-78.79%
366.039
2.507
2.779
-92.95%
53.27%
-51.76%

What the Analysts think about INO

Analyst Ratings

Majority rating from 6 analysts.
Buy

INO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$30M
21.60%
Profit margin
0.00%
-100.00%

INO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 30.56%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.56
-$1.56
-$1.12
-$1.31
-
Expected
-$1.74
-$1.52
-$1.27
-$1.00
-$1.10
Surprise
-10.34%
2.63%
-11.64%
30.56%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals (INO) has a market cap of $262M as of June 20, 2024.

What is the P/E ratio for Inovio Pharmaceuticals stock?

The price to earnings (P/E) ratio for Inovio Pharmaceuticals (INO) stock is 0 as of June 20, 2024.

Does Inovio Pharmaceuticals stock pay dividends?

No, Inovio Pharmaceuticals (INO) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Inovio Pharmaceuticals dividend payment date?

Inovio Pharmaceuticals (INO) stock does not pay dividends to its shareholders.

What is the beta indicator for Inovio Pharmaceuticals?

Inovio Pharmaceuticals (INO) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Inovio Pharmaceuticals stock price target?

The target price for Inovio Pharmaceuticals (INO) stock is $18.92, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Inovio Pharmaceuticals stock

Buy or sell Inovio Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing